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SUMMARY 
Cefotetan, a new broad-spectrum 7a-methoxycephalosporin antibiotic, was assayed in 
plasma and urine by means of reversed-phase high-performance liquid chromatography. 
Commercially available cefotetan exists in two epimeric forms. The procedure described 
allows the separation and quantitation of both. epimers. For the first time a different 
pharmacokinetic behaviour (tti = 3 h versus 4 h) for each epimer after intravenous injection 
to healthy volunteers is demonstrated. It is assumed that one epimer is bound to a greater 
extent to serum proteins and is therefore responsible for the differences observed. As both 
epimers exhibit similar antibacterial activity, it seems doubtful whether these differences 
would have clinical significance. Iothalamic acid was determined simultaneously as a 
marker of kidney function. 
INTRODUCTION 
Cefotetan disodium is a new 7a-methoxycephalosporin with a wide spectrum 
of antibacterial activity and remarkable stability against various /3-lactamases. 
Pharmacokinetic parameters in man have been studied in different races [l-4]. 
The commercially available product consists of a mixture of two epimers 
because of the asymmetric carbon atom at the dithietan ring. In this paper the 
R and S epimers are called A and B, respectively, because the absolute 
configuration was not known. In weakly alkaline media the two epimers are 
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Fig. 1. Chemical structure of cefotetan. The asterisk marks the epimeric centre and the posi- 
tion of this carbon atom in the tautomer. 
in equilibrium with a third tautomeric form (Fig. 1). Under physiological con- 
ditions the proportion of the tautomer is small, as demonstrated by others [l, 
4). The aim of the present study was to elucidate the pharrnacokinetic 
behaviour of both epimers of cefotetan after intravenous injection of the drug 
in healthy volunteers. 
MATERIALS AND METHODS 
Reagents 
Cefotetan was provided by ICI-Pharma (Plankstadt, F.R.G.), Conray 70@ 
(meglumine iothalamate) and iothalamic acid {3-(acetylamino)-2,4,6-triiodo-5- 
[ (methylamino)carbonyl] -benzoic acid} by Byk-Gulden (Konstanz, F.R.G.); 
acetonitrile and dichloromethane (ChromAR) were obtained from Promochem 
(Wesel, F.R.G.), the primary and secondary sodium phosphates (analytical 
grade) from Merck (Darmstadt, F.R.G.), and tetrabutylammonium bromide 
(purum) from Fluka (Neu-Ulm, F.R.G.). Water was purified with a Milli-Q 
water purification system (Millipore, Neu-Isenburg, F.R.G.). 
The stock solutions of cefotetan and iothalamic acid were prepared in 50 
mA4 sodium phosphate buffer (pH 6.2) to yield final concentrations of 1.0 
mg/ml and 10.0 mg/ml, and stored in aliquots at -2O’C. The stock solutions 
were then diluted with drug-free plasma to provide assay standards over a con- 
centration range of 1.25-100 kg/ml for cefotetan and 12.5-1000 E.cg/ml for 
iothalamic acid. For urine samples the standard solutions were prepared in 
50 n-&f phosphate buffer (pH 6.2). 
Analysis a f plasma and urine samples 
A 200-111 volume of plasma was buffered with 200 ~1 of 0.1 M sodium di- 
hydrogen phosphate and mixed for 5 set with 400 ~1 of acetonitrile on a Reax 
1 shaker (Heidolph, Kelheim, F.R.G.). After 15 min at 4°C the mixture was 
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centrifuged (1 min, 10,500 g) and the clear supernatant ransferred to a 12 X 
75 mm disposable polypropylene tube. Then 2.0 ml of dichloromethane were 
added, the tube was capped and mixed (5 min) on a Reax 2 Mixer (Heidolph). 
After centrifugation (10 min, 4800 g) an aliquot (5-50 ~1) of the upper 
aqueous phase was injected onto the column. 
Urine samples were centrifuged (10 min, 4800 g) and diluted 1:lO with 
50 m&Z sodium dihydrogen phosphate (resulting pH 5.8-5.9). 
AR biological samples were stored at -70°C until required for analysis. 
Chromatography 
The chromatographic system consisted of a pump M 6OOOA, a fixed-wave- 
length detector M 440 allowing simultaneous measurement at 254 and 286 nm, 
an automatic injector WISP ‘710 B, a data module M 730 and a system 
controller M 720 (all from Waters Assoc., Konigstein/Ts., F.R.G.). A Hibar@ 
stainless-steel column (125 X 4 mm I.D.), prepacked with 5-um LiChrosorb RI’- 
18 silica (Merck), was used for separation. The flow-rate was maintained at 
1.0 ml/min, the resulting back-pressure was 110-115 bar. The eluent was 
monitored at 254 and 280 nm, integrating the peak area of the signals at 280 
nm. For plasma samples the mobile phase was prepared by combining 925 ml 
of water, 75 ml of acetonitrile, 5.50 g of sodium dihydrogen phosphate mono- 
hydrate, 1.80 g of disodium hydrogen phosphate dihydrate and 20 mg of tetra- 
butylammonium bromide. For urine samples the contents of acetonitrile and 
tetrabutylammonium bromide were changed to 45-50 ml/l and 22.5 mg/l, 
respectively. The apparent pH of the buffered solutions was about 6.4. 
RESULTS 
Sample clean-up 
The major disadvantage of high-performance liquid chromatography (HPLC) 
in comparison with the microbiological assay is the need to remove proteins 
from the samples before injection onto the analytical column. In order to main- 
tain the precision, a minimal number of clean-up steps (e.g. pipetting or 
extracting) is desirable. Deproteinization is usually performed by adding 
organic solvents or acids. Ultrafiltration seems to be a very fast and simple 
technique and was used for the determination of cefmenoxime in plasma; but 
addition of sodium dodecylsulphate (SDS), a highly protein-bound displacing 
agent, is necessary to recover the protein-bound fraction of the drug [ 51. By 
adding 0.5% SDS we obtained nearly quantitative recoveries of both epimers of 
cefotetan from plasma using the sample clean-up procedure described under 
Materials and methods. However, the ion-pairing properties of SDS in reversed- 
phase HPLC caused chromatographic aberrations with peak splitting. De- 
proteinization by addition of perchloric acid resulted m low recoveries because 
of apparent co-precipitation of cefotetan. After sample clean-up by extraction 
of the cephalosporin and iothalamic acid into chloroform-pentanol as 
described in ref. 6, we obtained 90% recovery for both epimers of cefotetan 
and 70% recovery for iothalamic acid. Because of its simplicity for routine use, 
we preferred the procedure described under Materials and methods which is a 
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modificatjon of other methods known from the literature [ 7-91. Acetonitfile 
aCta as an efficient Protein precipitation agent. In the following extra&ion step 
with dichloromethane, neutral lipophilic substances as well as the acetonitrile 
used for protein precipitation, are removed. The cephalosporin remains in the 
undiluted aqueous layer. Using this procedure we achieved quantitative 
recoveries from biological fluids for the following acid compounds: cefadroxil, 
cefotaxime, desacetylcefotaxime, cefotiam, cefmenoxime, cefsulodin, 
ceftazidime and iothalamic acid. For cefotetan the recovery was 85% for epimer 
A and 98% for epimer B. On the other hand, the recovery for a neutral 
compound, namely desacetylcefotaxime lactone, was only 10%. 
Chromatography 
In Fig. 2 the chromatograms of an aqueous standard and plasma samples 
after simultaneous intravenous injection of 1 g of cefotetan and 20 ml of 
Conray 70 (containing 13.2 g of iothalamic acid) are depicted. The best 
compromise between run-time and separation of the isomers of cefotetan from 
each other and from endogenous compounds was obtained by adding small 
quantities (0.1 mA4) of tetrabutylammonium salt to the buffered (pH 6.3-6.5) 
mixture of water and acetonitrile. For urine samples it was necessary to lower 
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Fig. 2. Chromatograms of (1) an aqueous standard solution of cefotetan (CTN, commercially 
available mixture of epimers A and B) and iothalamic acid (ITS) (amount injected: ITS, 
5 bg; CTN, 500 ng) and of plasma samples from a healthy volunteer 10 min (2), 2 h (3) and 
6 h (4) after simultaneous intravenous injection of 1 g of cefotetan and 20 ml of Conray 
70 (corresponding to 13.2 g of iothalamic acid). Concentrations (Mg/ml): (2) ITS, 849; 
CTN-A, 56.4; CTN-B, 72.8. (3) ITS, 204; CTN-A, 29.5; CTN-B, 29.9. (4) ITS, 27.8; CTN-A, 
10.2; CTN-B, 7.3. 
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Fig. 3. Chromatogmms of (1) an aqueous standard solution of cefotetan (CTN) and 
iothalamic acid (ITS) (amount injected: ITS, 5 .ug; CTN, 500 ng) and of urine samples from 
a healthy volunteer O-2 h (2) and 4-6 h (3) after simultaneous intravenous injection of 1 g 
of cefotetan and 20 ml of Conray 70 (corresponding to 13.2 g of iothalamic acid). 
Concentrations (kg/ml): (2) ITS, 9870; CTN-A, 325; CTN-B, 502. (3) ITS, 2370; CTN-A, 
376; CTN-B, 342. 
the acetonitrile content and to change the concentration of the ion-pairing 
agent in order to maintain the separation from interfering compounds. As a 
consequence the overall run-time increased to 15 min compared to 8 min for 
plasma samples (Fig. 3). 
Recovery and sensltwity 
The recoveries of iothalamic acid and cefotetan were checked in the con. 
centration range 12.5-1000 pg/ml and 1.25-100 pg/ml, respectively. TWO sets 
of spiked plasma samples were prepared and each analysed two times on 
different days. The peak areas found were compared with those of standard 
aqueous solutions. The results are shown in Table I. The mean recoveries were 
100.3 + 2.4% for iothalamic acid, 84.6 + 2.2% for isomer A of cefotetan and 
97.6 f 2.4% for isomer B, The recoveries from aqueous samples were 95.1 * 
2.0%, 93.7 + 3.2% and 93.6 + 3.7%, respectively. Obviously, the recovery of 
isomer A from plasma was substantially lower than the recoveries of the other 
two compounds. The recoveries of the individual spiked plasma samples 
fluctuated between 74 and 118%. For quantitation of the concentrations found 
in the unknown plasma samples, the mean value was used. The regression lines 
LL_Z- ,.-I ._ ~11 nn=nr= h-d rnrwlntion coeffjcjen~ better than 0.9996. . 
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TABLE I 
RECOVERY OF IOTHALAMIC ACID AND CEFOTETAN (EPIMERS A AND B) FROM 
HUMAN PLASMA 
Amount added Recovery* (%) 
(pglml) 
ITS/CTN Iothalamic Cefotetan (CTN) 
acid 
(ITS) Epimer A Epimer B 
1000/100 100.7 f 4.9 86.4 t 1.1 97.4 f 3.3 
500150 102.8 t 3.8 87.0 + 2.6 98.3 f 1.6 
250125 101.7 i- 3.3 84.7 + 2.6 97.0 ?I 0.8 
lOO/lO 100.1 + 3.9 85.5 + 7.3 96.7 r 4.3 
5015 102.2 + 7.9 83.6 ? 5.1 102.5 * 10.6 
2512.5 98.8 k 3.8 80.4 +_ 6.6 94 7 + 1.5 
12.5 Il.25 95.9 + 9 7 84.4 f 11.3 96.6 + 12 4 
Mean + S.D. 100.3 + 2.4 84.6 k 2.2 97 6 ? 2.4 
*Mean + S.D.; n = 4. 
is low at 280 nm (X,, = 240 nm; see also Figs. 2 and 3). For an injection 
volume of 50 ~1 this would correspond to a limit of detection of 20-40 ng/ml 
and 200-400 ng/ml, respectively. This analytical limit of detection could not 
be reached in biological fluids. In all plasma samples interfering compounds 
correspondmg to up to 1 pg/ml of iothalamic acid were present, whereas in a 
few samples only an interfering peak corresponding to not more than 0.2 pg/ml 
of epimer B of cefotetan occurred. The blanks observed in urine were about ten 
times higher. Since up to 12 h after administration the concentrations of 
iothalamic acid were much higher than the blank values, no attempt was made 
to eliminate the unusually high blank value. 
Sample stability 
Especially if automatic injection systems are used for overnight runs, samples 
must be stable at room temperature . fi-Lactam antibiotics are labile in weak 
basic and strong acid media. The pH of plasma samples kept at room 
temperature rises to 9 [lo]. Therefore plasma samples containing 
cephalosporins should be buffered to a neutral or weak acid pH 151. Following 
the preparation procedure described in this report, no degradation of cefotetan 
or iothalamic acid was measurable within 12 h. Moreover, at the resulting pH of 
5.8-6.0 the ratio of the two epimers of cefotetan was constant too, whereas 
in unbuffered plasma samples (final pH 8.2-8.3 after sample clean-up) the 
amount of A increased and that of B decreased in samples with prevalent 
isomer B. Iothalamic acid was also stable in unbuffered samples. 
Application 
The analytical method described above was used to determine simultaneous- 
ly both epimers of cefotetan and iothalamic acid in plasma and urine after intra- 
venous injection of 1 g of cefotetan and 20 ml of Conray 70 (containing 13.2 g 
nf i~th~l~mir arid\ fnr nhnmnpnkinpf,ip st,lldies_ Toth&mic acid is nearly 
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Fig. 4. Mean plasma concentrations of cefotetan (CTN, epimers A and B) and iothalamic 
acid (ITS) after simultaneous intravenous injection of 1 g of cefotetan and 20 ml of Conray 
70 (corresponding to 13.2 g of iothalamic acid) to 12 healthy volunteers. (a), ITS; (+), 
CTN (A + B); (A), CTN-A; (v), CTN-B. 
exclusively eliminated through the kidney by glomerular filtration and served 
in this study as marker for the function of the kidney [ll] . A detailed report 
will be published elsewhere [12]. In Fig. 4 the mean plasma concentrations of 
cefotetan obtained from twelve healthy volunteers are shown. As can be seen, 
the time-concentration curve of isomer A is flatter. The terminal half-life was 
about 3 h for isomer B and 4 h for isomer A, respectively. These data are in 
agreement with average half-lives of cefotetan found by others [l-4]. 
Immediately after cessation of the injection the ratio A/B was 40:60 and the 
reversed after 12 h. The observed isomerisation in proteinaceous solutions was 
confirmed in vitro by incubation of cefotetan in phosphate buffer and 7% 
bovine serum albumin (BSA) at pH 7.4. As can be seen in Fig. 5, within 18 h 
the ratio shifted nearly to 50:50 in buffer, whereas in BSA solution the 
resulting ratio (70:30) was similar to that in plasma of volunteers. 
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DISCUSSION 
Beside the microbiological assay, HPLC has been established as a standard 
method to determine cephalosporins in biological matrices. Because of its 
precision, high linear range and possibility to detect and assay active 
metabolites quantitatively, as in the case of the 3-acetoxycephalosporins [7, 
131, HPLC is the preferred method for pharmacokinetic studies. In addition, 
after simultaneous application of different antibiotics, separation and quantita- 
tion of the various compounds can be achieved. 
In the present paper a different pharmacokinetic behaviour of each epimer 
of cefotetan has been demonstrated. The reason for this effect is probably a 
higher ratio of protein binding of epimer A, which can be assumed from the 
observed lower recovery after deproteinisation with acetonitrile, and the 
isomerisation in BSA solution leading to another ratio of the epimers than in 
buffer. On the other hand, lower stability of epimer B could contribute to this 
effect too, because in BSA solution degradation of cefotetan is enhanced with 
respect to the buffer (Fig. 5). Similar results were obtained from work with 
moxalactam. Commercially available moxalactam preparations are also 
mixtures of two epimers with slightly different protein-binding ratios, 
biological half-lives and antimicrobial activities [14-191, As both epimers of 
cefotetan have a similar antibacterial activity 1201, probably no clinical 
consequences will result from the finding of different serum half-lives for the 
isomers. Whether accumulation of isomer A will occur in plasma or other body 
fluids after multiple doses of cefotetan seems questionable, since both epimers 
are presumably in equilibrium with each other. The analytical method 
described in the present paper could clarify this problem during further clinical 
trials. 
Fig. 6. Degradation of cefotetan (mixture of epimers A and B) at 37”C, pH = 7.4, in 0.1 M 
sodium phosphate buffer (0, l ) and 7% bovine serum albumin (BSA) solution (a, A). 
Increase in fraction of epimer A. 
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